1 / 64

Presenting Gonexin

Presenting Gonexin. Providing hope through extension and enhancement of life. MBA Consulting Team Larry Morkre Matt Narens Rick Silva, Ph.D. Brian Weninger. December 13, 2001. Concept.

basil
Download Presentation

Presenting Gonexin

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Presenting Gonexin Providing hope through extension and enhancement of life MBA Consulting Team Larry Morkre Matt Narens Rick Silva, Ph.D. Brian Weninger December 13, 2001 Confidential

  2. Concept Gonexin is a revolutionary, patented “smart drug” for cancer treatment. We have the expertise to guide Gonexin to commercial success in a market with huge profit potential. Confidential

  3. Management and Leadership Introduction Opportunity Technology Financial Summary Questions • Dr. Paul Jarosz • Chief Operating Officer • Involved in commercial development of 58 pharmaceutical products • Clinical development executive with Geneva Pharmaceuticals (Novartis), Johnson & Johnson, and Syntex (Roche) Confidential

  4. Management and Leadership Introduction Opportunity Technology Financial Summary Questions • Dr. Terry Nett • Cofounder and board member • Internationally recognized expert in GnRH biology • Dr. Mike Glode • Cofounder and board member • Internationally recognized researcher in prostate cancer biology • Consultant on clinical trials for Leupron and Abarelix Confidential

  5. Global Pharmaceutical Market $400 B Introduction Opportunity Technology Financial Summary Questions 2003 Confidential

  6. Industry Trends Introduction Opportunity Technology Financial Summary Questions • Trend away from toxic to “smart drugs” • Shift from healthcare spending to pharmaceutical spending • Small R & D firms have innovative advantage Confidential

  7. Market Growth Potential Introduction Opportunity Technology Financial Summary Questions • Up to 15% growth in human pharmaceutical market • High risk begins at age 50 • Aging population Confidential

  8. Our Position Introduction Opportunity Technology Financial Summary Questions Confidential

  9. Introduction Opportunity Technology Financial Summary Questions Market Share Growth 79,000 late stage cases of prostate cancer treated annually Confidential

  10. Marketing Strategy Introduction Opportunity Technology Financial Summary Questions • Industry publications Confidential

  11. Marketing Strategy Introduction Opportunity Technology Financial Summary Questions • Trade shows Confidential

  12. Marketing Strategy Introduction Opportunity Technology Financial Summary Questions • Annual scientific and clinical meetings • Dedicated direct sales team • Web presence Confidential

  13. Bright Future Introduction Opportunity Technology Financial Summary Questions • We are an innovative Research and Development organization • Other potential indications for Gonexin • Breast cancer • Colon cancer • Uterine cancers • Pancreatic cancer • Some forms of lung cancer Confidential

  14. The Product Introduction Opportunity Technology Financial Summary Questions • Gonexin • Two therapeutic indications-Prostate Cancer • Hormone therapy • Chemotherapy • Leupron, Zolodex, and Viadur only offer hormone therapy mechanism • Other Epithelial Cancers Confidential

  15. Normal Physiology Introduction Opportunity Technology Financial Summary Questions GnRH Receptor Gonadotroph Non Target Cell Confidential

  16. Normal Physiology Introduction Opportunity Technology Financial Summary Questions GnRH Receptor Gonadotroph Non Target Cell Confidential

  17. Normal Physiology Introduction Opportunity Technology Financial Summary Questions GnRH Receptor Gonadotroph Non Target Cell Confidential

  18. Normal Physiology Introduction Opportunity Technology Financial Summary Questions GnRH Receptor Gonadotroph Non Target Cell Confidential

  19. Normal Physiology Introduction Opportunity Technology Financial Summary Questions GnRH Gonadotroph Receptor Non Target Cell Confidential

  20. Normal Physiology Introduction Opportunity Technology Financial Summary Questions GnRH Receptor Gonadotroph Non Target Cell Confidential

  21. Normal Physiology Introduction Opportunity Technology Financial Summary Questions GnRH Receptor Gonadotroph Non Target Cell Testosterone Confidential

  22. Normal Physiology Introduction Opportunity Technology Financial Summary Questions GnRH Receptor Gonadotroph Non Target Cell Testosterone Confidential

  23. Normal Physiology Introduction Opportunity Technology Financial Summary Questions GnRH Receptor Gonadotroph Non Target Cell Testosterone Confidential

  24. Normal Physiology Introduction Opportunity Technology Financial Summary Questions GnRH Receptor Gonadotroph Non Target Cell Testosterone Confidential

  25. Normal Physiology Introduction Opportunity Technology Financial Summary Questions GnRH Receptor Gonadotroph Non Target Cell Testosterone Confidential

  26. Hormone Therapy Mechanism Introduction Opportunity Technology Financial Summary Questions Leupron Receptor Gonadotroph Non Target Cell Confidential

  27. Hormone Therapy Mechanism Introduction Opportunity Technology Financial Summary Questions Leupron Receptor Gonadotroph Non Target Cell Confidential

  28. Hormone Therapy Mechanism Introduction Opportunity Technology Financial Summary Questions Leupron Receptor Gonadotroph Non Target Cell Confidential

  29. Hormone Therapy Mechanism Introduction Opportunity Technology Financial Summary Questions Leupron Receptor Gonadotroph Non Target Cell Confidential

  30. Hormone Therapy Mechanism Introduction Opportunity Technology Financial Summary Questions Leupron Receptor Gonadotroph Non Target Cell Confidential

  31. Hormone Therapy Mechanism Introduction Opportunity Technology Financial Summary Questions Leupron Receptor Gonadotroph Non Target Cell Confidential

  32. Hormone Therapy Mechanism Introduction Opportunity Technology Financial Summary Questions Leupron Receptor Gonadotroph Non Target Cell Confidential

  33. Hormone Therapy Mechanism Introduction Opportunity Technology Financial Summary Questions Leupron Receptor Gonadotroph Non Target Cell Confidential

  34. Hormone Therapy Mechanism Introduction Opportunity Technology Financial Summary Questions Leupron Receptor Gonadotroph Non Target Cell Confidential

  35. Hormone Therapy Mechanism Introduction Opportunity Technology Financial Summary Questions Leupron Receptor Gonadotroph Non Target Cell Confidential

  36. Hormone Therapy Mechanism Introduction Opportunity Technology Financial Summary Questions GnRH Receptor Gonadotroph Non Target Cell Testosterone Confidential

  37. Chemotherapy Mechanism Introduction Opportunity Technology Financial Summary Questions GnRH-Toxin Receptor Gonadotroph Non Target Cell GnRH-Toxin Receptor Cancer Healthy Cell Confidential

  38. Chemotherapy Mechanism Introduction Opportunity Technology Financial Summary Questions GnRH-Toxin Receptor Gonadotroph Non Target Cell GnRH-Toxin Receptor Cancer Healthy Cell Confidential

  39. Chemotherapy Mechanism Introduction Opportunity Technology Financial Summary Questions GnRH-Toxin Receptor Gonadotroph Non Target Cell GnRH-Toxin Receptor Cancer Healthy Cell Confidential

  40. Chemotherapy Mechanism Introduction Opportunity Technology Financial Summary Questions GnRH-Toxin Receptor Gonadotroph Non Target Cell GnRH-Toxin Receptor Cancer Healthy Cell Confidential

  41. Chemotherapy Mechanism Introduction Opportunity Technology Financial Summary Questions GnRH-Toxin Receptor Gonadotroph Non Target Cell GnRH-Toxin Receptor Cancer Healthy Cell Confidential

  42. Chemotherapy Mechanism Introduction Opportunity Technology Financial Summary Questions GnRH-Toxin Receptor Gonadotroph Non Target Cell GnRH-Toxin Receptor Cancer Healthy Cell Confidential

  43. Chemotherapy Mechanism Introduction Opportunity Technology Financial Summary Questions GnRH-Toxin Receptor Gonadotroph Non Target Cell GnRH-Toxin Receptor Cancer Healthy Cell Confidential

  44. Chemotherapy Mechanism Introduction Opportunity Technology Financial Summary Questions GnRH-Toxin Receptor Gonadotroph Non Target Cell GnRH-Toxin Receptor Cancer Healthy Cell Confidential

  45. Chemotherapy Mechanism Introduction Opportunity Technology Financial Summary Questions GnRH-Toxin Receptor Non Target Cell GnRH-Toxin Receptor Healthy Cell Confidential

  46. Chemotherapy Mechanism Introduction Opportunity Technology Financial Summary Questions GnRH-Toxin Receptor Non Target Cell GnRH-Toxin Receptor Healthy Cell Confidential

  47. Chemotherapy Mechanism Introduction Opportunity Technology Financial Summary Questions Non Target Cell Healthy Cell Confidential

  48. Chemotherapy Mechanism Introduction Opportunity Technology Financial Summary Questions Non Target Cell Healthy Cell Confidential

  49. Chemotherapy Mechanism Introduction Opportunity Technology Financial Summary Questions Non Target Cell Healthy Cell Confidential

  50. Chemotherapy Mechanism Introduction Opportunity Technology Financial Summary Questions Non Target Cell Healthy Cell Confidential

More Related